CAMBRIDGE, England–ReNeuron, a leading UK-based stem cell company, today announced the publication of a paper in the journal Biotechnology Letters demonstrating successful automation of the manufacturing of its ReN001 neural stem cell line for stroke in TAP’s CompacT SelecT™ automated cell culture system.

The research was conducted in collaboration with the REMEDI project at Loughborough University. ReNeuron’s standard cell manufacturing process was adapted and transferred to CompacT SelecT which then successfully manufactured a batch of neural stem cells. The growth rate and the quality characteristics of the cells were identical to those manufactured manually.

Dr John Sinden, Chief Scientific Officer of ReNeuron, said: “The successful automation of our ReN001 manufacturing process heralds two exciting advances. Firstly, ReNeuron has access to a precise platform allowing optimization of its cell culture process, leading to lower costs and increased yield. Secondly, we anticipate that automation will deliver a more reliable scale of manufacture progressing the therapy into later stage trials and beyond.”

Professor David Williams, Director of the Research School of Health and Life Sciences at Loughborough University, commented: “The automation of therapeutic stem cell manufacturing is a critical to the development of scalable, reproducible, regulatory compliant and hence commercially viable stem cell products. We look forward to further collaboration with ReNeuron, a world leader in the development of scalable stem cells, to demonstrate the value of automated cell manufacturing platforms in the later stage development of their clinical stem cell products.”